Non-Small-Cell Lung Cancer – Epidemiology – Europe

Allemani C, et al. Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet. 2018;391(10125):1023-1075 [LINK]

BCR. Belgium Cancer Registry. https://kankerregister.org. 2021. [LINK]

Boch C, et al. The frequency of EGFR and KRAS mutations in non-small cell lung cancer (NSCLC): routine screening data for central Europe from a cohort study. BMJ Open. 2013 Apr 3;3(4):e002560. [PUBMED]

Bozzetti C, et al. Epidermal growth factor receptor and Kras gene expression: reliability of mutational analysis on cytological samples. Diagn Cytopathol. 2013 Jul;41(7):595-8. [PUBMED]

Brancher S, et al. Metformin use and lung cancer survival: a population-based study in Norway Br J Cancer. 2021; 124(5):1018-1025 [PubMed]

Bratova M, et al. Non-small Cell Lung Cancer as a Chronic Disease – A Prospective Study from the Czech TULUNG Registry In Vivo. 2020; 34(1):369-379 [PubMed]

Carrato A, et al. Clinical management patterns and treatment outcomes in patients with non-small cell lung cancer (NSCLC) across Europe: EPICLIN-Lung study, Current Medical Research and Opinion,30:3, 447-461 [Pubmed]

Cheng H, et al. Survival Disparities in Black Patients With EGFR-mutated Non-small-cell Lung Cancer. Clin Lung Cancer. 2020 Mar;21(2):177-185. [PUBMED]

Clérigo V, et al. Characterization and management of elderly and very elderly patients with non-small cell lung cancer Clin Respir J. 2020; 14(7):683-686 [PubMed]

CNCR. Czech National Cancer Registry. Institute of Health Information and Statistics of the Czech Republic (UZIS CR) in cooperation with the National Oncological Registry of the Czech Republic. Cancer Incidence in the Czech Republic. http://www.uzis.cz/en/registers/national-health-re. 2022 [LINK]

Colombino M, et al. EGFR, KRAS, BRAF, ALK, and cMET genetic alterations in 1440 Sardinian patients with lung adenocarcinoma. BMC pulmonary medicine. 2019 Dec;19(1):1-0. [Pubmed]

CRN. Cancer Registry of Norway. Cancer in Norway – Cancer incidence, mortality, survival and prevalence in Norway. 2018 [LINK]

D’Angelo SP, et al. Distinct clinical course of EGFR-mutant resected lung cancers: results of testing of 1118 surgical specimens and effects of adjuvant gefitinib and erlotinib. J Thorac Oncol. 2012 Dec;7(12):1815-1822. [PUBMED]

Debieuvre D, 2019 et al. Evidence of slight improvement in five-year survival in non-small-cell lung cancer over the last 10 years: Results of the French KBP-CPHG real-world studies. Bull Cancer. 2019 Apr;106(4):283-292. doi: 10.1016/j.bulcan.2019.01.010. Epub 2019 Feb 23 [Pubmed]

ECIS. European Cancer Information System. 2019 [LINK]

Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A, (editors). AJCC cancer staging manual, 7th edition. France: Springer; 2010 [Link}

Ekman S, et al. Epidemiology and Survival Outcomes for Patients With NSCLC in Scandinavia in the Preimmunotherapy Era: A SCAN-LEAF Retrospective Analysis From the I-O Optimise Initiative JTO Clin Res Rep. 2021; 2(5):100165 [PubMed]

Evans M, et al. Large-Scale EGFR Mutation Testing in Clinical Practice: Analysis of a Series of 18,920 Non-Small Cell Lung Cancer Cases. Pathol Oncol Res. 2019 Oct;25(4):1401-1409. [PUBMED]

Faehling M, et al. Oncogenic driver mutations, treatment, and EGFR-TKI resistance in a Caucasian population with non-small cell lung cancer: survival in clinical practice. Oncotarget. 2017 Sep 13;8(44):77897-77914. [PUBMED]

Fedewa SA, Kazerooni EA, Studts JL, et al. State Variation in Low-Dose Computed Tomography Scanning for Lung Cancer Screening in the United States. J Natl Cancer Inst. 2021;113(8):1044-1052 [Pubmed]

Fedewa SA, Bandi P, Smith RA, Silvestri GA, Jemal A. Lung Cancer Screening Rates During the COVID-19 Pandemic. Chest. 2022;161(2):586-589 [Pubmed]

Finn SP, et al. Prognostic Impact of KRAS G12C Mutation in Patients With NSCLC: Results From the European Thoracic Oncology Platform Lungscape Project. J Thorac Oncol. 2021 Jun;16(6):990-1002. [PUBMED]

Fukui T, et al. Clinicoradiologic characteristics of patients with lung adenocarcinoma harboring EML4-ALK fusion oncogene. Lung Cancer. 2012; 77(2):319-25 [Pubmed]

Gandara DR, et al. Association of epidermal growth factor receptor activating mutations with low ERCC1 gene expression in non-small cell lung cancer. J Thorac Oncol. 2010 Dec;5(12):1933-8. [PUBMED]

Griesinger F, et al. Biomarker testing in non-small cell lung cancer in routine care: Analysis of the first 3,717 patients in the German prospective, observational, nation-wide CRISP Registry (AIO-TRK-0315). Lung Cancer. 2021 Feb;152:174-184. [PUBMED]

González M, et al. Overall survival for early and locally advanced non-small-cell lung cancer from one institution: 2000-2017 Clin Transl Oncol. 2021; 23(7):1325-1333 [PubMed]

Grosse A, et al. Analysis of the frequency of oncogenic driver mutations and correlation with clinicopathological characteristics in patients with lung adenocarcinoma from Northeastern Switzerland. Diagnostic pathology. 2019 Dec;14(1):1-4. [Pubmed]

Guerreiro T, et al. Lung cancer survival and sex-specific patterns in Portugal: A population-based analysis Pulmonology. 2021; – [PubMed]

Hansen MS, Licaj I, Braaten T, Lund E, Gram IT. The fraction of lung cancer attributable to smoking in the Norwegian Women and Cancer (NOWAC) Study. Br J Cancer. 2021;124(3):658-662 [Pubmed]

Hedgeman E, et al. Programmed cell death ligand-1 expression and survival in a cohort of patients with non-small cell lung cancer receiving first-line through third-line therapy in Denmark Cancer Epidemiol. 2021; 73:101976 [PubMed]

Hoque M, et al. Genetic and epigenetic analysis of erbB signaling pathway genes in lung cancer. J Thorac Oncol. 2010 Dec;5(12):1887-93. [PUBMED]

IARC. International Agency for Research on Cancer. Cancer Incidence in Five Continents, Vol. XI. IARC Scientific Publications, Lyon, IARC. 2018 [Link]

Jakobsen E, et al. Forecasting lung cancer incidence, mortality, and prevalence to year 2030 BMC Cancer. 2021; 21(1):985 [PubMed]

Judd J, et al. Characterization of KRAS Mutation Subtypes in Non-small Cell Lung Cancer. Mol Cancer Ther. 2021 Dec;20(12):2577-2584. [PUBMED]

Kee D, Wisnivesky J, Kale MS. Lung Cancer Screening Uptake: Analysis of BRFSS 2018. J Gen Intern Med. 2021;36(9):2897-2899 [Pubmed]

Kerr KM, et al. Prevalence and clinical association of gene mutations through multiplex mutation testing in patients with NSCLC: results from the ETOP Lungscape Project. Ann Oncol. 2018 Jan 1;29(1):200-208. [PUBMED]

Kobayashi M, et al. Clinical significance of BRAF gene mutations in patients with non-small cell lung cancer. Anticancer Res. 2011 Dec;31(12):4619-23. [PUBMED]

Koga T, et al. CHFR hypermethylation and EGFR mutation are mutually exclusive and exhibit contrastive clinical backgrounds and outcomes in non-small cell lung cancer. Int J Cancer. 2011 Mar 1;128(5):1009-17. [PUBMED]

Kuroda H, et al. Contribution of smoking habit to the prognosis of stage I KRAS-mutated non-small cell lung cancer. Cancer Biomark. 2018;23(3):419-426. [PUBMED]

Jemal A, Fedewa SA. Lung Cancer Screening With Low-Dose Computed Tomography in the United States-2010 to 2015. JAMA Oncol. 2017;3(9):1278-1281 [Pubmed]

Li J, Chung S, Wei EK, Luft HS. New recommendation and coverage of low-dose computed tomography for lung cancer screening: uptake has increased but is still low. BMC Health Serv Res. 2018;18(1):525. Published 2018 Jul 5 [Pubmed]

Linardou H, et al. Genotyping KRAS and EGFR Mutations in Greek Patients With Non-small-cell Lung Cancer: Incidence, Significance and Implications for Treatment. Cancer Genomics Proteomics. 2019 Nov-Dec;16(6):531-541. [PUBMED]

Lin E, et al. Exon Array Profiling Detects EML4-ALK Fusion in Breast, Colorectal, and Non–Small Cell Lung Cancers. Mol Cancer Res. 2009 Sep;7(9):1466-76. [Pubmed]

Löfling L, et al. Temporal trends in lung cancer survival: a population-based study Acta Oncol. 2021; – [PubMed]

Lopez-Chavez A, et al. Molecular profiling and targeted therapy for advanced thoracic malignancies: a biomarker-derived, multiarm, multihistology phase II basket trial. J Clin Oncol. 2015 Mar 20;33(9):1000-7. [PUBMED]

Maki- Nevala S, et al. Epidermal growth factor receptor mutations in 510 Finnish non–small-cell lung cancer patients. J Thorac Oncol. 2014 Jun;9(6):886-91. [PUBMED]

Mäki-Nevala S, et al. Hot spot mutations in Finnish non-small cell lung cancers. Lung Cancer. 2016 Sep;99:102-10. [PUBMED]

Marchetti A, et al. Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutations. J Clin Oncol. 2011 Sep 10;29(26):3574-9. [PUBMED]

Mitra D, et al. EGFR mutant locally advanced non-small cell lung cancer is at increased risk of brain metastasis. Clin Transl Radiat Oncol. 2019 Jun 27;18:32-38. [PUBMED]

Mizuno T, et al. Impact of the oncogenic status on the mode of recurrence in resected non-small cell lung cancer. Jpn J Clin Oncol. 2016 Oct;46(10):928-934. [PUBMED]

Mizuno T, et al. Current outcomes of postrecurrence survival in patients after resection of non-small cell lung cancer. J Thorac Dis. 2018 Mar;10(3):1788-1796. [PUBMED]

Mochinaga K, et al. High expression of dihydropyrimidine dehydrogenase in lung adenocarcinoma is associated with mutations in epidermal growth factor receptor: implications for the treatment of non–small-cell lung cancer using 5-fluorouracil. Clin Lung Cancer. 2014 Mar;15(2):136-144.e4. [PUBMED]

Molinier O, et al. Five-year survival and prognostic factors according to histology in 6101 non-small-cell lung cancer patients. Respir Med Res. 2020 Mar;77:46-54. [PUBMED]

Moore DA, et al. Analysis of a large cohort of non-small cell lung cancers submitted for somatic variant analysis demonstrates that targeted next-generation sequencing is fit for purpose as a molecular diagnostic assay in routine practice. J Clin Pathol. 2018 Nov;71(11):1001-1006. [PUBMED]

Moyer VA; U.S. Preventive Services Task Force. Screening for lung cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2014;160(5):330-338 [Pubmed]

Muller P, et al. Temporal and geographic changes in stage at diagnosis in England during 2008-2013: A population-based study of colorectal, lung and ovarian cancers Cancer Epidemiol. 2020; 67:101743 [PubMed]

Nakamura R, et al. Epidermal growth factor receptor mutations: effect on volume doubling time of non-small-cell lung cancer patients. J Thorac Oncol. 2014 Sep;9(9):1340-4. [PUBMED]

NCI. National Cancer Institute. Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence – SEER Research Data, 18 Registries, Nov 2020 Sub (2000-2018) – Linked To County Attributes – Time Dependent (1990-2018) Income/Rurality, 1969-2019 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, released April 2021, based on the November 2020 submission [Link]

Netherlands Cancer Registry (NKR), Netherlands Comprehensive Cancer Organization (IKNL), derived via www.iknl.nl/en/ncr/ncr-data-figures [12.07.2022]. [LINK]

NICER. Foundation National Institute for Cancer Epidemiology and Registration. Cancer Statistics. http://www.nicer.org/en/statistics-atlas/cancer-in. 2019 [LINK]

NORDCAN. Larønningen S, Ferlay J, Beydogan H, Bray F, Engholm G, Ervik M, Gulbrandsen J, Hansen HL, Hansen HM, Johannesen TB, Kristensen S, Kristiansen MF, Kønig S, Lam F, Laversanne M, Miettinen J, Mørch LS, Ólafsdóttir E, Óskarsson O, Pejicic S, Petterson D, Skog A, Skovlund CW, Tanskanen T, Tian H, Virtanen A, Aagnes B, Storm HH (2022). NORDCAN: Cancer Incidence, Mortality, Prevalence and Survival in the Nordic Countries, Version 9.2 (23.06.2022). Association of the Nordic Cancer Registries. Cancer Registry of Norway. Available from: https://nordcan.iarc.fr/, accessed on 12/07/2022 [LINK]

Ogawa K, et al. Can smoking duration alone replace pack-years to predict the risk of smoking-related oncogenic mutations in non-small cell lung cancer? A cross-sectional study in Japan. BMJ Open. 2020 Sep 9;10(9):e035615. [PUBMED]

Ohba T, et al. Mutations of the EGFR, K-ras, EML4-ALK, and BRAF genes in resected pathological stage I lung adenocarcinoma. Surg Today. 2016 Sep;46(9):1091-8. [PUBMED]

O’Keeffe LM, Taylor G, Huxley RR, Mitchell P, Woodward M, Peters SAE. Smoking as a risk factor for lung cancer in women and men: a systematic review and meta-analysis. BMJ Open. 2018;8(10):e021611 [Pubmed]

Oki M, et al. Feasibility and accuracy of molecular testing in specimens obtained with small biopsy forceps: comparison with the results of surgical specimens. Respiration. 2015;89(3):235-42. [PUBMED]

Ou SH, et al. Association of ALK resistance mutations by EML4-ALK variant (v3 vs. non-v3) in ALK+ non-small cell lung cancer (NSCLC). Oncology. 2017. 35, no. 15_suppl 9010-9010. [Link]

Parikh AB, et al. A pooled analysis of two phase II trials evaluating metformin plus platinum-based chemotherapy in advanced non-small cell lung cancer. Cancer Treat Res Commun. 2019;20:100150. [PUBMED]

Park S, Jee SH, Shin HR, et al. Attributable fraction of tobacco smoking on cancer using population-based nationwide cancer incidence and mortality data in Korea. BMC Cancer. 2014;14:406. Published 2014 Jun 6 [Pubmed]

Pasello G, et al. From Diagnostic-Therapeutic Pathways to Real-World Data: A Multicenter Prospective Study on Upfront Treatment for EGFR-Positive Non-Small Cell Lung Cancer (MOST Study). Oncologist. 2019 Jun;24(6):e318-e326. [PUBMED]

Pesch B, Kendzia B, Gustavsson P, et al. Cigarette smoking and lung cancer–relative risk estimates for the major histological types from a pooled analysis of case-control studies. Int J Cancer. 2012;131(5):1210-1219 [Pubmed]

Righi L, et al. Detection and characterization of classical and “uncommon” exon 19 Epidermal Growth Factor Receptor mutations in lung cancer by pyrosequencing. BMC Cancer. 2013 Mar 13;13:114. [PUBMED]

Röntgengesellschaft D. Deutsche Röntgengesellschaft: Mit Lungenkrebsfrüherkennung Durch Niedrigdosis-CT Schließt Sich Eine Lücke In Der Gesundheitsversorgung.; 2022. Accessed June 8, 2022. [Link]

Sandfeld-Paulsen B, et al. Hyponatremia in lung cancer: Incidence and prognostic value in a Danish population-based cohort study Lung Cancer. 2021; 153:42-48 [PubMed]

Sandfeld-Paulsen B, et al. Pretreatment Albumin-to-Alkaline Phosphatase Ratio Is a Prognostic Marker in Lung Cancer Patients: A Registry-Based Study of 7077 Lung Cancer Patients Cancers (Basel). 2021; 13(23):6133 [PubMed]

Saito T, et al. Preoperative renal dysfunction and long-term survival after surgery for non-small cell lung cancer J Thorac Cardiovasc Surg. 2021; – [PubMed]

Sasaki H, et al. Nras and Kras mutation in Japanese lung cancer patients: Genotyping analysis using LightCycler. Oncol Rep. 2007 Sep;18(3):623-8. [PUBMED]

Sato H, et al. Analysis of bevacizumab treatments and metastatic sites of lung cancer Cancer Treat Res Commun. 2021; 26:100290 [PubMed]

Schuurman MS, et al. Temporal trends and spatial variation in stage distribution of non-small cell lung cancer in the Netherlands. OA Epidemiology 2014 Jul 18;2(1):10. [LINK]

Sekine I, et al. A Japanese lung cancer registry study on demographics and treatment modalities in medically treated patients Cancer Sci. 2020; 111(5):1685-1691 [PubMed]

Shaukat I, et al. Detection of RAS and RAS-associated alterations in primary lung adenocarcinomas. A correlation between molecular findings and tumor characteristics. Hum Pathol. 2019 Feb;84:18-25. [PUBMED]

Shire NJ, et al. STK11 (LKB1) mutations in metastatic NSCLC: Prognostic value in the real world. PLoS One. 2020 Sep 3;15(9):e0238358. [PUBMED]

Simarro J, et al. Development, Implementation and Assessment of Molecular Diagnostics by Next Generation Sequencing in Personalized Treatment of Cancer: Experience of a Public Reference Healthcare Hospital. Cancers (Basel). 2019 Aug 16;11(8):1196. [PUBMED]

Singal G, et al. Association of patient characteristics and tumor genomics with clinical outcomes among patients with non–small cell lung cancer using a clinicogenomic database. Jama. 2019 Apr 9;321(14):1391-9. [Pubmed]

Snee M, et al. Treatment patterns and survival outcomes for patients with non-small cell lung cancer in the UK in the preimmunology era: a REAL-Oncology database analysis from the I-O Optimise initiative BMJ Open. 2021; 11(9):e046396 [PubMed]

Sørensen JB, et al. Initial treatment and survival in Danish patients diagnosed with non-small-cell lung cancer (2005-2015): SCAN-LEAF study Future Oncol. 2022; 18(2):205-214 [PubMed]

Sousa AC, et al. Detection of rare and novel EGFR mutations in NSCLC patients: Implications for treatment-decision. Lung Cancer. 2020 Jan;139:35-40. [PUBMED]

Statistics Austria. Federal Statistical Office, Austria. Statistics Austria – Cancer Statistics. 2021 [LINK]

Stella GM, et al. EGFR and KRAS mutational profiling in fresh non-small cell lung cancer (NSCLC) cells. J Cancer Res Clin Oncol. 2013 Aug;139(8):1327-35. [PUBMED]

Suda K, et al. Clinical Impacts of EGFR Mutation Status: Analysis of 5780 Surgically Resected Lung Cancer Cases. Ann Thorac Surg. 2021 Jan;111(1):269-276. [PUBMED]

Sun F, et al. Cardiovascular mortality and morbidity following radical radiotherapy for lung cancer: Is cardiovascular death under-reported? Lung Cancer. 2020; 146:1-5 [PubMed]

Takahashi T, et al. Clinicopathologic features of non-small-cell lung cancer with EML4–ALK fusion gene. Annals of surgical oncology. 2010 Mar;17(3):889-97. [Pubmed]

Tamiya A, et al. Impact of somatic mutations on prognosis in resected non-small-cell lung cancer: The Japan Molecular Epidemiology for lung cancer study. Cancer Med. 2020 Apr;9(7):2343-2351. [PUBMED]

Ulivi P, et al. Assessment of EGFR and K-ras mutations in fixed and fresh specimens from transesophageal ultrasound-guided fine needle aspiration in non-small cell lung cancer patients. Int J Oncol. 2012 Jul;41(1):147-52. [PUBMED]

United Nations. Department of Economic and Social Affairs. Population Division. World Population Prospects: The 2015 Revision. Released 29 July 2015. [Link]

Vallee A, et al. Detection of EGFR gene mutations in non-small cell lung cancer: lessons from a single-institution routine analysis of 1,403 tumor samples. Int J Oncol. 2013 Oct;43(4):1045-51. [PUBMED]

VanderLaan PA, et al. Tumor biomarker testing in non-small-cell lung cancer: A decade of change. Lung Cancer. 2018 Feb;116:90-95. [PUBMED]

Vanthomme K, et al. Lung cancer incidence differences in migrant men in Belgium, 2004-2013: histology-specific analyses BMC Cancer. 2021; 21(1):328 [PubMed]

Venclicek O, et al. Lung Cancer in Non-smokers in Czech Republic: Data from LUCAS Lung Cancer Clinical Registry Anticancer Res. 2021; 41(11):5549-5556 [PubMed]

Verleye L, De Gendt C, Vrijens F, et al. Patterns of care for non-small cell lung cancer patients in Belgium: A population-based study. Eur J Cancer Care (Engl). 2018;27(1):10.1111/ecc.12747. [PubMed]

Vidal J, et al. Assessment of ALK Status by FISH on 1000 Spanish Non-Small Cell Lung Cancer Patients. J Thorac Oncol. 2014 Dec;9(12):1816-20. [Pubmed]

Willén L, et al. Are older patients with non-small cell lung cancer receiving optimal care? A population-based study Acta Oncol. 2022; 61(3):309-317 [PubMed]

Winther-Larsen A, et al. Inflammation-scores as prognostic markers of overall survival in lung cancer: a register-based study of 6,210 Danish lung cancer patients BMC Cancer. 2022; 22(1):63 [PubMed]

Wojciechowska Urszula, Didkowska Joanna . Illnesses and deaths from malignant neoplasms in Poland. National Cancer Registry, National Oncology Institute Maria Skłodowskiej-Curie – National Research Institute. Available at http://onkologia.org.pl/raporty/ access on 14/07/2022. [LINK]

Wormanns D, Kauczor HU, Antoch G, et al. Joint Statement of the German Radiological Society and the German Respiratory Society on a Quality-Assured Early Detection Program for Lung Cancer with Low-Dose CT. Positionspapier der Deutschen Röntgengesellschaft und der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin zu einem qualitätsgesicherten Früherkennungsprogramm des Lungenkarzinoms mittels Niedrigdosis-CT. Rofo. 2019;191(11):993-997 [Pubmed]

Yong PC, Sigel K, Rehmani S, Wisnivesky J, Kale MS. Lung Cancer Screening Uptake in the United States [published correction appears in Chest. 2020 Oct;158(4):1797]. Chest. 2020;157(1):236-238 [Pubmed]

ZfKD. Zentrums für Krebsregisterdaten. German Center for Cancer Registry Data. RKI. Robert Koch Institute. 2019 [Link]

ZfKD. Cancer in Germany 2017/2018. 13th edition. Robert Koch Institute (ed.) and the Association of Population-based Cancer Registries in Germany (ed.). Berlin, 2022 [Link]